1. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. (10th April 2018) Authors: Wirsching, H -G; Tabatabai, G; Roelcke, U; Hottinger, A F; Jörger, F; Schmid, A; Plasswilm, L; Schrimpf, D; Mancao, C; Capper, D; Conen, K; Hundsberger, T; Caparrotti, F; von Moos, R; Riklin, C; Felsberg, J; Roth, P; Jones, D T W; Pfister, S; Rushing, E J Journal: Annals of oncology Issue: Volume 29:Number 6(2018) Page Start: 1423 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. (30th March 2018) Authors: Gramatzki, D; Roth, P; Rushing, E J; Weller, J; Andratschke, N; Hofer, S; Korol, D; Regli, L; Pangalu, A; Pless, M; Oberle, J; Bernays, R; Moch, H; Rohrmann, S; Weller, M Journal: Annals of oncology Issue: Volume 29:Number 6(2018) Page Start: 1431 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P01.108 Use of complementary and alternative medicine in glioma patients. (19th September 2018) Authors: Hertler, C; Roelcke, U; Conen, K; Huber, F; Weiss, T; Hofer, S; Heese, O; Westphal, M; Roth, P; Weller, M; Eisele, G Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P10.20.A Mechanisms of synergistic glioma growth suppression by radiotherapy and MET inhibition. (5th September 2022) Authors: Silginer, M; Papa, E; Szabo, E; Vasella, F; Pruschy, M; Stroh, C; Roth, P; Weiss, T; Weller, M Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P10.19.B An immunotoxin targeting CD317 for the treatment of glioblastoma. (5th September 2022) Authors: Gramatzki, D; Weiss, T; Hänsch, L; Silginer, M; Rushing, E J; Roth, P; Gramatzki, M; Peipp, M; Weller, M Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OS08.8.A Integrin-specific CAR T cells for the treatment of glioblastoma. (5th September 2022) Authors: Villars, D; Hänsch, L; Silginer, M; Weiss, T; Weller, M; Roth, P Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. OS08.7.A Lomustine and the immunocytokine L19TNF are a promising treatment combination for recurrent glioblastoma. (5th September 2022) Authors: Look, T; Puca, E; Stucchi, R; Luca, R; Roth, P; Neri, D; Weller, M; Hemmerle, T; Weiss, T Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. The role of perinatal palliative care following prenatal diagnosis of major, incurable fetal anomalies: a multicentre prospective cohort study. (8th November 2021) Authors: de Barbeyrac, C; Roth, P; Noël, C; Anselem, O; Gaudin, A; Roumegoux, C; Azcona, B; Castel, C; Noret, M; Letamendia, E; Stirnemann, J; Ville, Y; Lapillonne, A; Viallard, M‐L; Kermorvant‐Duchemin, E Other Names: Boize Philippe investigator.; Parat Sophie investigator.; Dugelay Frédéric investigator.; Stern Raphaëlla investigator.; Quibbel Thibault investigator.; Boileau Pascal investigator.; Ernault Pauline investigator. Journal: BJOG Issue: Volume 129:Number 5(2022) Page Start: 752 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PL03.3.A Development and characterization of CD317-specific CAR T cells as an innovative immunotherapeutic strategy against glioblastoma. (9th September 2021) Authors: Hänsch, L; Peipp, M; Myburgh, R; Silginer, M; Weiss, T; Gramatzki, D; Vasella, F; Manz, M; Weller, M; Roth, P Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. OS10.6 Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study. (6th September 2019) Authors: Lassman, A B; Sepúlveda-Sánchez, J M; Cloughesy, T; Gil-Gil, J M; Puduvalli, V K; Raizer, J; De Vos, F Y; Wen, P Y; Butowski, N; Clement, P; Groves, M D; Belda-Iniesta, C; Steward, K; Moran, S; Ye, Y; Roth, P Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 3 Page Start: iii21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗